Cargando...
Tolerability and safety of real-world use of pomalidomide in patients with relapsed/refractory multiple myeloma
Pomalidomide (POM) is a second-generation immunomodulatory agent with proven efficacy in patients with relapsed/refractory multiple myeloma (RRMM) proven to be refractory to previous treatment with lenalidomide (LEN) and bortezomib. We herein conducted a retrospective analysis of 14 RRMM patients re...
Gardado en:
| Publicado en: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
D.A. Spandidos
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6327207/ https://ncbi.nlm.nih.gov/pubmed/30680210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1775 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|